Advertisement

Stem Cell Therapy

  • Shinya Minatoguchi
Chapter

Abstract

Bone marrow-derived mononuclear cells (BM-MNCs) and mesenchymal stem cells (MSCs) have been considered candidate cell sources for stem cell therapy against AMI because animal studies using these cells showed beneficial effects. However, clinical trials using BM-MNCs and MSCs demonstrated their safety but their beneficial effects were small in patients with AMI. Therefore, a new cell source is required for stem cell therapy. Muse cells showed greater effects to reduce the myocardial infarct size and improve the cardiac function than MSCs. Muse cells showed differentiation into cardiomyocytes and vessels as well as paracrine effects. Muse cell therapy may be a promising and epoch-making stem cell therapy for the treatment of AMI. Clinical trials are warranted.

Keywords

Muse cells Mesenchymal stem cells Cardiomyocyte regeneration Infarct size Cardiac function 

References

  1. 1.
    Misao Y, Takemura G, Arai M, Sato S, Suzuki K, Miyata S, Kosai K, Minatoguchi S, Fujiwara T, Fujiwara H. Bone marrow-derived myocyte-like cells and regulation of repair-related cytokines after bone marrow cell transplantation. Cardiovasc Res 2006; 69: 476–490.CrossRefGoogle Scholar
  2. 2.
    Hou M, Yang KM, Zhang H, Zhu WQ, Duan FJ, Wang H, Song YH, Wei YJ, Hu SS Transplantation of mesenchymal stem cells from human bone marrow improves damaged heart function in rats. Int J Cardiol 2007; 115:220–228CrossRefGoogle Scholar
  3. 3.
    Nagaya N, Fujii T, Iwase T, Ohgushi H, Itoh T, Uematsu M, Yamagishi M, Mori H, Kangawa K, Kitamura S. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am J Physiol Heart Circ Physiol 2004; 287:H2670–2676CrossRefGoogle Scholar
  4. 4.
    George JC. Stem cell therapy in acute myocardial infarction: a review of clinical trials. Transl Res 2010; 155: 10–19.CrossRefGoogle Scholar
  5. 5.
    Fisher SA, Zhang H, Doree C, Mathur A, Martin-Rendon E. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2015; 9: CD006536.Google Scholar
  6. 6.
    Kuroda Y, Kitada M, Wakao S, Nishikawa K, Tanimura Y, Makinoshima H, Goda M, Akashi H, Inutsuka A, Niwa A, Shigemoto T, Nabeshima Y, Nakahata T, Nabeshima Y, Fujiyoshi Y, Dezawa M. Unique multipotent cells in adult human mesenchymal cell populations. Proc Natl Acad Sci U S A 2010; 107:8639–43.CrossRefGoogle Scholar
  7. 7.
    Alessio N, Ozcan S, Tatsumi K, Murat A, Peluso G, Dezawa M, Galderisi U. The secretome of MUSE cells contains factors that may play a role in regulation of stemness, apoptosis and immunomodulation. Cell Cycle 2016;  https://doi.org/10.1080/15384101.2016.1211215, 33, 44, 16.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Dezawa M. Muse cells provide the pluripotency of mesenchymal stem cells: direct contribution of Muse cells to tissue regeneration. Cell Transplant 2016; 25:849–861.CrossRefGoogle Scholar
  9. 9.
    Yamada Y, Wakao S, Kushida Y, Minatoguchi S, Mikami A, Higashi K, Baba S, Shigemoto T, Kuroda Y, Kanamori H, Amin M, Kawasaki M, Nishigaki K, Taoka M, Isobe T, Muramatsu C, Dezawa M, Minatoguchi S. S1P-S1PR2 axis mediates homing of Muse cells into damaged heart for long lasting tissue repair and functional recovery after acute myocardial infarction. Circ Res 2018; 122: 1069–1083.CrossRefGoogle Scholar
  10. 10.
    Freyman T, Polin G, Osman H, Crary J, Lu M, Cheng L, Palasis M, Wilensky RL. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 2006; 27:1114–1122.CrossRefGoogle Scholar
  11. 11.
    Tanaka T, Nishigaki K, Minatoguchi S, Nawa T, Yamada Y, Kanamori H, Mikami A, Ushikoshi H, Kawasaki M, Dezawa M, Minatoguchi S. Mobilized Muse cells after acute myocardial infarction predict cardiac function and remodeling in the chronic phase. Circ J 2018; 82: 561–571.CrossRefGoogle Scholar
  12. 12.
    Witt BJ, Jacobsen SJ, Weston SA, Killian JM, Meverden RA, Allison TG et al. Cardiac rehabilitation after myocardial infarction in the community. J Am Coll Cardiol 2004; 44: 988–996.CrossRefGoogle Scholar
  13. 13.
    Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease: cochrane systematic review and meta-analysis. J Am Coll Cardiol. 2016; 67:1–12.CrossRefGoogle Scholar
  14. 14.
    Minatoguchi S, Ando T, Tanaka T, Yamada Y, Kanamori H, Kawasaki M, Nishigaki K, Minatoguchi S. Cardiac rehabilitation with dynamic exercise increases the number of Muse cells in the peripheral blood of patients with heart disease. Circ Rep 2019; 1: 17–19.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Shinya Minatoguchi
    • 1
  1. 1.Head of Heart Failure Center, Gifu Municipal HospitalEmeritus Professor, Gifu University Graduate School of MedicineGifuJapan

Personalised recommendations